Hypothalamic-Pituitary Axis (HPA/HPG/HPT)

The hypothalamic-pituitary system is the neuroendocrine command center — the brain's interface with the hormone system. The hypothalamus receives neural inputs about metabolic state, stress, circadian rhythm, and temperature, then releases specific peptide hormones that instruct the pituitary gland to produce downstream hormones. Nearly every peptide therapy acts somewhere along these axes.

Architecture

The system follows a three-tier hierarchy:

1. Hypothalamus (brain) → releases stimulating/inhibiting peptides
2. Anterior pituitary → releases tropic hormones into circulation
3. Target glands (gonads, adrenals, thyroid, liver) → release effector hormones

Each axis has negative feedback: the effector hormone feeds back to suppress hypothalamic and pituitary output, maintaining homeostasis. Peptide therapies typically intervene at level 1 or 2.

The major axes

HP-GH Axis (Growth Hormone)

Hypothalamus: GHRH (stimulates) + Somatostatin (inhibits)

Pituitary: Somatotrophs release GH in pulses

Target: Liver produces IGF-1; direct GH effects on tissues

Feedback: IGF-1 → hypothalamus (↑ somatostatin, ↓ GHRH)

Peptides that intervene:

• GHRH analogs (CJC-1295, Sermorelin, Tesamorelin) → mimic GHRH signal
• GHRPs (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) → amplify pulse via GHSR-1a
• Combined CJC-1295 + Ipamorelin → dual GHRH-R + GHSR stimulation

Key principle: These peptides stimulate endogenous GH production through natural pulsatile pathways. Unlike exogenous recombinant GH (which suppresses the axis via negative feedback), GH secretagogues work with the axis and preserve physiological pulsatility.

HPG Axis (Gonadal / Reproductive)

Hypothalamus: GnRH (pulsatile release)

Pituitary: Gonadotrophs release LH + FSH

Target: Gonads produce testosterone (men) or estrogen/progesterone (women)

Feedback: Sex steroids → hypothalamus (↓ GnRH pulse frequency/amplitude)

Peptides that intervene:

• Gonadorelin (synthetic GnRH) → stimulates LH/FSH release when given in pulsatile fashion
• Kisspeptin-10 → stimulates GnRH release (upstream of GnRH neurons)

Key principle: GnRH must be pulsatile to stimulate the axis. Continuous GnRH exposure (as with Leuprolide/Lupron) paradoxically suppresses LH/FSH — this is how medical castration works. Pulsatile gonadorelin stimulates; continuous GnRH suppresses.

HPA Axis (Stress / Adrenal)

Hypothalamus: CRH (corticotropin-releasing hormone)

Pituitary: Corticotrophs release ACTH

Target: Adrenal cortex produces cortisol

Feedback: Cortisol → hypothalamus + pituitary (↓ CRH, ↓ ACTH)

Peptides that intervene:

• Semax (ACTH 4-10 fragment) → nootropic/neurotrophic effects without adrenal stimulation (fragment doesn't activate MC2R for cortisol release)
• Selank → modulates HPA reactivity, reducing stress-hormone output

Key principle: The HPA axis is the stress-response system. Chronic activation (chronic cortisol elevation) suppresses immune function, degrades muscle, and impairs cognition. Selank's anxiolytic effect partly works through dampening HPA overactivity.

HPT Axis (Thyroid)

Hypothalamus: TRH (thyrotropin-releasing hormone)

Pituitary: Thyrotrophs release TSH

Target: Thyroid produces T4 → peripheral conversion to T3

Feedback: T3/T4 → hypothalamus + pituitary (↓ TRH, ↓ TSH)

Peptides that intervene: Thymulin has thyroid-modulatory properties (the thymus-thyroid cross-talk). No major commercial peptide directly targets the HPT axis for thyroid stimulation. GH-axis peptides can indirectly affect T4→T3 conversion.

Why peptide interventions preserve axis function

The critical advantage of peptide-based hormone optimization over direct hormone replacement:

| Approach | Axis effect | Pulsatility | Feedback |

|----------|-------------|-------------|----------|

| Exogenous GH (somatropin) | Suppresses endogenous GH via IGF-1 feedback | Absent (continuous levels) | Disrupted |

| GH secretagogues (CJC/Ipa) | Preserves/enhances endogenous GH | Maintained (amplified pulses) | Intact |

| Exogenous testosterone (TRT) | Suppresses LH/FSH → testicular shutdown | N/A | Disrupted |

| Gonadorelin (pulsatile) | Stimulates LH/FSH → endogenous T production | Maintained | Intact |

This is why GH secretagogues are preferred over rGH for anti-aging: they work with the body's regulatory system rather than overriding it.

Age-related axis decline

All hypothalamic-pituitary axes decline with age:

• GH axis: GH pulse amplitude decreases ~14% per decade after 30 ("somatopause")
• HPG axis: Testosterone declines ~1–2% per year after 30 (men); menopause terminates ovarian function (women)
• HPA axis: Cortisol clearance slows; chronic mild elevation emerges
• HPT axis: TSH sensitivity decreases; subclinical hypothyroidism prevalence increases

Peptide interventions aim to restore youthful axis function rather than bypass the axis entirely. The goal is renewed responsiveness, not permanent override.

Monitoring axis function

When using peptides that target hypothalamic-pituitary axes, monitoring confirms you're achieving the intended effect:

| Axis | Key markers | Frequency |

|------|-------------|-----------|

| GH | IGF-1, GH (stimulated) | Baseline + 4–8 weeks |

| HPG | Total/free testosterone, LH, FSH | Baseline + 6–8 weeks |

| HPA | AM cortisol, DHEA-S | As clinically indicated |

| HPT | TSH, free T4, free T3 | Baseline + 6–8 weeks |

Bottom line

The hypothalamic-pituitary axes are the body's neuroendocrine operating system. Peptide therapies (GHRH analogs, GHRPs, gonadorelin, Selank) intervene at the hypothalamic or pituitary level to modulate hormonal output while preserving the feedback loops and pulsatile patterns that maintain long-term axis health. This preservation of physiological regulation is the primary pharmacological advantage of peptide-based approaches over direct hormone replacement.